

ONO PHARMACEUTICAL CO., LTD. (“the Company”)

Fiscal year ended March 31, 2022

Business Description

The Company and its subsidiaries (the “Group”) and the Group’s associate are engaged in business related to the pharmaceutical field. As of March 31, 2022, there were 11 subsidiaries and one associate.

The positions, etc. of the Company and its subsidiaries and associate in the pharmaceutical business are as follows.

<Pharmaceutical business>

The Group manufactures and sells medical and general pharmaceutical products, etc. Among these products, the Group has been focusing particularly on research & development activities for prescription drugs, and they are positioned as a key area within our corporate group.

[Subsidiaries and associates]

(Sales, sales support, etc.)

ONO PHARMA KOREA CO., LTD., ONO PHARMA TAIWAN CO., LTD.

(Manufacturing and sales)

Ono Pharma Healthcare Co., Ltd., TOYO Pharmaceutical Co., Ltd., BEE BRAND MEDICO DENTAL CO., LTD., NAMICOS CORPORATION

(Clinical development, and in-licensing and out-licensing activities for pharmaceuticals)

ONO PHARMA USA, INC., ONO PHARMA UK LTD.

(Other)

Ono Venture Investment, Inc.


Ono Venture Investment. Fund I, L.P.

Ono Digital health Investment, GK.

One other company

Segment information is omitted herein, because the business of the Group and the Group’s associates is a single segment of the pharmaceutical business.

The following business organization chart shows the matters described above.



Information on Subsidiaries and Associates

(As of March 31, 2022)

Name	Address	Capital or investments in capital	Principal businesses	Ratio of voting rights held (%)	Relationship
(Consolidated subsidiaries)		Millions of U.S. dollars			
ONO PHARMA USA, INC. (Note 2)	Massachusetts, U.S.	24	Pharmaceutical business	100.0	Clinical development, in-licensing and out-licensing activities, etc. for pharmaceuticals.
ONO PHARMA UK LTD.	London, U.K.	Thousands of U.K. pounds 50	Pharmaceutical business	100.0	Clinical development, in-licensing and out-licensing activities, etc. for pharmaceuticals.
ONO PHARMA KOREA CO., LTD.	Seoul Special City, Republic of Korea	Millions of Korean Republic won 3,000	Pharmaceutical business	100.0	Sales, sales support, etc. for the Company's pharmaceuticals.
ONO PHARMA TAIWAN CO., LTD.	Taipei City, Taiwan	Millions of New Taiwan dollars 90	Pharmaceutical business	100.0	Sales, sales support, etc. for the Company's pharmaceuticals.
TOYO Pharmaceutical Co., Ltd. (Note 3)	Chuo-ku, Osaka City, Japan	Millions of yen 21	Pharmaceutical business	45.5	Manufacturing, sales, etc. for pharmaceuticals. No. of officers concurrently holding positions: One
BEE BRAND MEDICO DENTAL CO., LTD.	Higashiyodogawa-ku, Osaka City, Japan	Millions of yen 10	Pharmaceutical business	80.0 (40.0)	Purchasing, sales, etc. for pharmaceuticals.
Ono Venture Investment, Inc.	California, U.S.	Millions of U.S. dollars 2	Pharmaceutical business	100.0	Investing in venture companies, etc., and fund management.
Ono Venture Investment Fund I, L.P.	California, U.S.	Millions of U.S. dollars 15	Pharmaceutical business	100.0 (1.0)	Investing in venture companies, etc.
Ono Pharma Healthcare Co., Ltd.	Chuo-ku, Osaka City, Japan	Millions of yen 10	Pharmaceutical business	100.0	Operation, etc. of a healthcare-related business.
Ono Digital health Investment, GK.	Chuo-ku, Tokyo, Japan	Millions of yen 10	Pharmaceutical business	100.0	Provision of funding to venture companies, etc., and supporting their business growth.
One other company					
(Associates accounted for using the equity method)		Millions of yen			
NAMICOS CORPORATION	Chuo-ku, Osaka City, Japan	45	Pharmaceutical business	18.8	Manufacturing, sales, etc. for pharmaceutical glassware.

(Notes) 1 The names used in the segment information are given in the "Principal businesses" column.

2 The company is a specified subsidiary.

- 3 Although the Company's equity stake in TOYO Pharmaceutical Co., Ltd. does not exceed 50%, it is treated as a subsidiary because it is effectively controlled by the Company.
- 4 The number within the () of the ratio of voting rights held is the ratio of voting rights which are indirectly held.
- 5 None of the companies file a securities registration statement or securities report.
- 6 None of the companies, which are the Company's subsidiaries and associate, have revenue that exceeds 10% of consolidated revenue (excluding internal sales revenue among consolidated companies).